CliffBio
small molecule

ZOMETA

ZOLEDRONIC ACID

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOMETA
Active ingredientZOLEDRONIC ACID
StrengthEQ 4MG BASE/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
7932241February 2028product

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZOMETA patent cliff — loss of exclusivity February 2028 | CliffBio